CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 2.9% on Thursday after an insider sold shares in the company. The company traded as low as $42.78 and last traded at $42.22. 282,558 shares ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and a rating upgrade by a Wall Street analyst. Though CRSP’s quarterly ...

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...

Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store. The rise in CRISPR Therapeutics' share price can be ...

Cathie Wood’s ARK ETFs capitalized on the pullback in Coinbase (COIN) and Robinhood (HOOD) stocks to load up additional shares on Thursday ...

Stocks: Real-time U.S. stock quotes reflect trades reported through ... Sources: FactSet, Tullett Prebon Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange ...

If an investor was to purchase shares of CRSP stock at the current price level of $43.03/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

Let’s delve into the company’s strengths and weaknesses to gain a better understanding of how to play the stock amid this price rise. CRSP/VRTX’s Strong Global Launch Efforts for Casgevy The ...